Sekisui XenoTech is a global contract research organization based in Kansas City, KS. The company hired a record number of new staff over the past year in order to meet current demand for its products and services, which are utilized to optimize the discovery, development, and approval of new drugs and other compounds. Several previous Sekisui XenoTech employees also returned to the company. The new staff span Sekisui XenoTech’s contract research, quality assurance, business, IT, and other departments.
“Our hiring efforts are a reflection of our commitment to maintaining strict quality standards while meeting client needs and timelines,” explained Toshinari Ohara, PhD, CEO of Sekisui XenoTech.
One of the new additions was industry veteran Darren Warren, PhD, who became the company’s new COO in October.
“I am excited to become a member of an organization with the distinguished performance history, leadership team strength, depth of scientific expertise, and position of market leadership that Sekisui XenoTech enjoys, and that holds an optimistic outlook towards future growth while maintaining commitment to excellence in providing a positive customer experience as well as outstanding contract services and products,” said Warren.
In addition to growth, the company has made other internal changes.
“While hiring talent from outside the organization has many positive effects, such as introducing new ideas and expertise, we have also been focused on ongoing training and career advancement for our existent staff,” said Ohara.
Sekisui XenoTech awarded numerous promotions to its staff this year, which prominently included elevating Joanna Barbara, PhD, to the position of Vice President of Scientific Operations and Brian Ogilvie, PhD, to the position of Vice President of Scientific Consulting. Joanna and Brian share a combined 30 years of experience with the company.